...
首页> 外文期刊>Journal of biomaterials applications >In vivo and in vitro analyses of the effects of a novel high-nitrogen low-nickel coronary stent on reducing in-stent restenosis
【24h】

In vivo and in vitro analyses of the effects of a novel high-nitrogen low-nickel coronary stent on reducing in-stent restenosis

机译:在体内和体外分析新型高氮镍冠状动脉支架降低支架内再狭窄的影响

获取原文
获取原文并翻译 | 示例

摘要

Currently, percutaneous coronary intervention is an important treatment for coronary heart disease. However, the in-stent restenosis rate is still approximately 10-30% after stenting. Nickel ions from the stent are considered to be associated with in-stent restenosis. Therefore, in the present study, we quantitatively evaluated in-stent restenosis after implanting the novel high-nitrogen low-nickel coronary stent (HNS) and studied the mechanism underlying the reduction in in-stent restenosis by using ELISA and Western blot. The in vivo results showed that the HNS could significantly reduce neointima formation and inflammation as compared to SUS316L stents (316L) at 180 days after implantation in porcine coronary arteries and that vascular endothelial growth factor-A expression in porcine coronary arteries after HNS implantation also decreased. The in vitro results showed that, in the case of the HNS, human umbilical vein endothelial cell (HUVEC) proliferation was lower and lesser IL-6 release was noted from HUVECs at one and three days after culture than in the 316L group. Furthermore, p-STAT3 expression in HUVECs on the HNS surface was downregulated after culture for seven days. Thus, we conclude that the HNS could be a promising alternative coronary stent for percutaneous coronary intervention.
机译:目前,经皮冠状动脉干预是冠心病的重要疗法。然而,支架后续再狭窄率仍然仍然约为10-30%。来自支架的镍离子被认为与支架内再狭窄有关。因此,在本研究中,我们在植入新型高氮镍冠状动脉(HNS)后定量评估了支架内再狭窄,并通过使用ELISA和Western印迹研究了在支架内再狭窄的降低的机制。在体内结果表明,与SUS316L支架(316L)在植入猪冠状动脉的180天内,HNS可以显着降低内部形成和炎症,并且HNS植入后猪冠状动脉中的表达也降低了血管内皮生长因子。体外结果表明,在HNS的情况下,人脐静脉内皮细胞(HUVEC)增殖较低,培养后一度和三天的HUVECS注意到较小的IL-6释放。此外,在HUS表面上的HUVEC中的P-STAT3表达在培养后下调七天。因此,我们得出结论,HNS可能是有前途的替代冠状动脉,用于经皮冠状动脉介入。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号